Department of Medical Research, Division of Translational Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Department of Dentistry, School of Dentistry, National Yang-Ming University, Taipei, Taiwan, ROC.
J Chin Med Assoc. 2020 Oct;83(10):891-894. doi: 10.1097/JCMA.0000000000000396.
As of April 15, 2020, the US Food and Drug Administration has granted emergency use authorization to a first saliva test for diagnosis of severe acute respiratory syndrome coronavirus 2 infection, the device developed by RUCDR Infinite Biologics laboratory, Rutgers University. A key feature that distinguishes the saliva-based test from nasopharyngeal or oropharyngeal (throat) swabs is that this kit allows self-collection and can spare healthcare professionals to be at risk during collecting nasopharyngeal or oropharyngeal samples, thereby preserving personal protective equipment for use in patient care rather than sampling and testing. Consequently, broader testing than the current methods of nasal or throat swabs will significantly increase the number of people screening, leading to more effective control of the spread of COVID-19. Nonetheless, a comparison of saliva-based assay with current swab test is needed to understand what and how we can benefit from this newly developed assay. Therefore, in this mini-review article, we aimed to summarize the current and emerging tools, focusing on diagnostic power of different clinical sampling and specimens.
截至 2020 年 4 月 15 日，美国食品和药物管理局已授予 RUCDR Infinite Biologics 实验室（罗格斯大学）开发的用于诊断严重急性呼吸系统综合征冠状病毒 2 感染的首个唾液检测试剂紧急使用授权。与鼻咽或口咽（喉咙）拭子相比，基于唾液的检测的一个关键特征是，该试剂盒允许自我采集，从而可以避免医护人员在采集鼻咽或口咽样本时面临风险，从而将个人防护设备用于患者护理而不是采样和检测。因此，与当前的鼻腔或喉咙拭子方法相比，更广泛的检测将大大增加筛查人数，从而更有效地控制 COVID-19 的传播。尽管如此，仍需要对基于唾液的检测与当前的拭子检测进行比较，以了解我们可以从这种新开发的检测中获得什么以及如何从中受益。因此，在这篇迷你综述文章中，我们旨在总结当前和新兴的工具，重点关注不同临床采样和标本的诊断能力。
